(Q34588761)

3 August 2017

1 reference

title

Arsenic trioxide: safety issues and their management (English)

1 reference

3 August 2017

1 reference

Wing-Yan Au

1

1 reference

PubMed ID

18298894

3 August 2017

Yok-Lam Kwong

series ordinal

2

1 reference

3 August 2017

1 March 2008

1 reference

Acta Pharmacologica Sinica

3 August 2017

1 reference

3 August 2017

29

1 reference

3 August 2017

296-304

1 reference

3 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1111/j.1745-7254.2008.00771.x

3 August 2017

0 references

cites work

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Prolongation of cardiac repolarization by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Mechanisms of arsenic-induced prolongation of cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Cardiac monitoring of patients receiving arsenic trioxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Effects of sodium arsenite exposure on development and behavior in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2008.00771.X

10.1111/J.1745-7254.2008.00771.X

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

18298894

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

18298894